Featured NewsNovo Nordisk reveals obesity drug with up to 22 percent weight lossbasrahdaily.comJanuary 24, 2025January 24, 2025 January 24, 2025January 24, 2025 Novo Nordisk shares surged 6.87% to $86.67 on Friday morning following the release of promising trial results for its new obesity treatment, amycretin. The company...